手機版
化工儀器網手機版
化工儀器網小程序
官方微信
公眾號：chem17
掃碼關注視頻號
枸櫞酸托法替尼背景及作用機理：
枸櫞酸托法替尼是由美國輝瑞制藥公司開發一種治療類風濕關節炎藥物，商品名Xeljanz，用于對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節炎（RA）成人患者。本產品是一種Janus激酶抑制劑，每日服用兩次。
2012年11月6日，美國食品藥品管理局(FDA)和輝瑞公司聯合宣布，枸櫞酸托法替尼獲準用于對氨甲喋呤治療應答不充分或不耐受的中至重度活動性類風濕關節炎(RA)成人患者。
Xeljanz可作為單一治療或與氨甲喋呤或其他非生物疾病緩解性抗風濕藥物(DMARD)聯合使用。該藥不應與生物性DMARD或強免疫抑制劑(如硫唑嘌呤和環孢菌素)聯合使用。經核準的Xeljanz劑量為每日2次，每次5mg。
深圳遠揚化學可提供托法替尼申報所用全套雜質， 隨貨附CoA證書，HNMR，MS，HPLC圖譜，純度符合申報要求，托法替尼雜質為我司優勢雜質，長期備有庫存，發貨快。如需托法替尼雜質相關詳細信息，歡迎我司業務人員獲取~
除自主品牌雜質對照品外，我司還代理英國NIBSC標準品，美國劍橋CIL同位素標準品，美國NIST標準物質，歐洲標準局IRMM標準物質，加拿大TRC標準品，TLC標準品，MOLCAN標準品，NRC標準品等，歡迎洽談。
附：托法替尼申報用雜質列表：
| Tofacitinib | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 1 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-1H-indol-4-amine |
| Tofacitinib Impurity 2 | 2-chloro-N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| Tofacitinib Impurity 3 | 3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 4 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 5 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxoprop* |
| Tofacitinib Impurity 6 | 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanoic acid |
| Tofacitinib Impurity 7 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-2-chloro-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| Tofacitinib Impurity 8 | N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride |
| Tofacitinib Impurity 9 | 3-((3R,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile compound with 3-((3S,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (1:1) |
| Tofacitinib Impurity 10 | 3-((3S,4S)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 11 | (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
| Tofacitinib Impurity 12 | (3S,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
| Tofacitinib Impurity 13 | (3S,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
| Tofacitinib Impurity 14 | (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride |
| Tofacitinib Impurity 15 | 3-((3R,4R)-3-(7H-[4,7'-bipyrrolo[2,3-d]pyrimidin]-4'-yl(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 16 | (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carbaldehyde |
| Tofacitinib Impurity 17 | N-methyl-N-((3R,4R)-4-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
| Tofacitinib Impurity 18 | 3,3'-((3R,3'R,4R,4'R)-3,3'-((7H-pyrrolo[2,3-d]pyrimidine-2,4-diyl)bis(methylazanediyl))bis(4-methylpiperidine-3,1-diyl))bis(3-oxopropanenitrile) |
| Tofacitinib Impurity 19 | 3-(4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)(methyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 20 | 3-((3R,4R)-3-((6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile |
| Tofacitinib Impurity 21 | N-((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine oxide |
| Tofacitinib Impurity 22 | (3R,4R)-1-(2-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N,4-dimethylpiperidin-3-amine hydrochloride |
| Tofacitinib Impurity 23 | (3R,4R)-N,4-dimethyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-amine |
| Tofacitinib Impurity 24 | N-((3R,4R)-1,4-dimethylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride |
| Tofacitinib Impurity 25 | 1-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)ethanone |
| Tofacitinib Impurity 26 | N-((3R,4S)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine compound with N-((3S,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (1:1) |
| Tofacitinib Impurity 27 | N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7-tosyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine |
免責聲明
- 凡本網注明“來源：化工儀器網”的所有作品，均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品，未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的，應在授權范圍內使用，并注明“來源：化工儀器網”。違反上述聲明者，本網將追究其相關法律責任。
- 本網轉載并注明自其他來源（非化工儀器網）的作品，目的在于傳遞更多信息，并不代表本網贊同其觀點和對其真實性負責，不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時，必須保留本網注明的作品第一來源，并自負版權等法律責任。
- 如涉及作品內容、版權等問題，請在作品發表之日起一周內與本網聯系，否則視為放棄相關權利。
采購中心